A Study to Evaluate the Safety and PK of CRN04894 for the Treatment of Cushing's Syndrome
A phase 1/2 trial of atumelnant in pituitary tumours and pituitary carcinoma, run by Crinetics Pharmaceuticals Inc., active and no longer recruiting.
Overview
A Study to Evaluate the Safety and PK of CRN04894 for the Treatment of Cushing's Syndrome is a phase 1/2 interventional study registered as NCT05804669 by Crinetics Pharmaceuticals Inc., with 19 participants enrolled, started 2023-10-12 and due to reach its primary completion in 2026-10. Interventions recorded: atumelnant.
Setting
A Phase 1b/2a Open-label Multiple-ascending Dose Exploratory Study of CRN04894 in ACTH-dependent Cushing's Syndrome (Cushing's Disease or Ectopic ACTH Syndrome)
Phase
Phase 1/2
Sponsor
Crinetics Pharmaceuticals Inc.
Registry
Enrolled
19
Similar pages
not linked directly; found by shared links- TrialA Study to Investigate Safety and Effectiveness of CRN09682 in Participants With SST2-Expressing NENs and Other Solid Tumors
Shares Crinetics Pharmaceuticals and the tag pipeline.
- TrialCarcinoid Syndrome Efficacy Study Featuring an Oral Daily Paltusotine Regimen
Shares Crinetics Pharmaceuticals and the tag pipeline.